Changchun BCHT Biotechnology Co. Stock: price and insider trades · China
百克生物
No insider purchase over the last 90 days. The latest, by 孔维, was filed 03 Apr 2023.
Changchun BCHT Biotechnology Co.: what insiders have been doing
Changchun BCHT Biotechnology Co. is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). Nothing new has been filed by managers of Changchun BCHT Biotechnology Co. in twelve months, the latest record being from 27 February 2024.
Over the whole record (from 2021), the tally stands at 2 purchases and 2 sales.
In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Since the insiders bought
- -21.4%Entry CN¥56.60 · Close at T+365 CN¥44.50
- -34.8%Entry CN¥101.51 · Close at T+365 CN¥66.22
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 45,000 shares41.1% of flowA股XSHGSSE:173000007346678370
- 187,913 shares100.0% of flowA股XSHGSSE:173000006446510270Canonical exit: 2 Jul 2023 (T+90)
- 50,000 shares58.9% of flowA股XSHGSSE:173000006261973300
- 600 shares100.0% of flowA股XSHGSSE:173000005038462800Canonical exit: 29 Sept 2021 (T+90)
4 of 4 declarations
About Changchun BCHT Biotechnology Co.
百克生物 is a company focused on the healthcare and pharmaceutical sector, specializing in the development of biopharmaceutical solutions. It is listed on the Shanghai Stock Exchange (XSHG).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
